BRYCE RICHARD PAUL 4
4 · PUMA BIOTECHNOLOGY, INC. · Filed May 6, 2020
Insider Transaction Report
Form 4
BRYCE RICHARD PAUL
SR VP, CLINICAL RESEARCH & DEV
Transactions
- Sale
COMMON STOCK
2020-05-04$9.62/sh−89$856→ 77,832 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.